The data strongly de-risks the myositis registrational program and adds a second pivotal indication in SSc, expanding the addressable market. The PC-free lupus data, while early, supports a potential market expansion thesis. Key catalysts to watch: SSc registrational study initiation in 4Q26, topline DM/ASyS registrational data in mid-2027, and PC-free dose-ranging data across indications. The favorable safety profile supporting outpatient administration could improve commercial adoption if approved.
Price Chart
Executive Summary
Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 2026, including 83% (5/6) of dermatomyositis patients meeting the registrational primary endpoint, encouraging early PC-free lupus data showing deep B cell depletion in 1 of 2 patients, and plans to initiate a systemic sclerosis registrational study in 4Q26. The company also announced a 2H27 BLA submission target for myositis including adult and pediatric data, with potential for a priority review voucher.
Key Facts
- 83% (5/6) of Phase 1/2 dermatomyositis patients achieved IM-free moderate-to-major TIS response at 16 weeks, meeting the registrational primary endpoint threshold
- All 5 DM responders maintained IM-free response through latest follow-up as long as 1.5 years
- First JDM patient achieved IM-free moderate TIS response at 16 weeks, maintained at 32 weeks; JDM to be included in 2H27 BLA submission
- Systemic sclerosis announced as second pivotal indication; single-arm registrational study of ~25 patients with ILD expected to start in 4Q26
- Lowest dose of PC-free rese-cel achieved deep B cell depletion in 1 of 2 lupus patients; second patient had ~90% B cell reduction
- 94% of first 63 patients with preconditioning had no CRS or Grade 1 CRS only; 97% had no ICANS
- BLA submission for adult DM and JDM planned for 2H27, potentially qualifying for a priority review voucher
- SSc patients with ILD showed median 7.5% improvement in FVC at 36 weeks off immunomodulators
Financial Impact
No financial data provided in filing; company is pre-revenue clinical-stage biotech with $572M market cap
Risk Factors
- Phase 1/2 data may not predict registrational trial outcomes; ASyS durability was variable
- PC-free data is very early (2 lupus patients); higher dose cohorts still enrolling
- BLA submission in 2H27 is over a year away; regulatory pathway and approval are uncertain
- Company is pre-revenue with no approved products; will require additional capital to fund registrational trials and commercialization
- Competition from other CD19-CAR T programs in autoimmunity and approved therapies (IVIg, brepocitinib, Vyvgart)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000030 |
| Document: caba-20260603.htm | 0001759138-26-000030 |
| Document: caba-ex99_1.htm | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index-headers.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030-index.html | 0001759138-26-000030 |
| Document: 0001759138-26-000030.txt | 0001759138-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access